Key Points {#d30e197}
==========

Opioid induced constipation is a medical condition that causes a substantial burden to the patient and the healthcare system.In clinical studies, oxycodone/naloxone has been shown to improve bowel function and is estimated to be cost-effective according to health economic models.

Introduction {#Sec1}
============

Chronic pain is a common and disabling condition, which can significantly affect quality of life (QoL) \[[@CR1]--[@CR5]\]. A variety of definitions may be used to define chronic pain; the International Association for the Study of Pain defines it as pain without apparent biological value that has persisted beyond the normal tissue healing time (usually taken to be 3 months) \[[@CR6]\]. In a large-scale survey of chronic pain (defined as pain lasting \>6 months with an intensity of ≥5 on a 1--10 scale) across 15 European countries plus Israel, prevalence rates of 12--30 % were reported \[[@CR2]\]. Prevalence rates, however, vary widely between studies because of differences in population characteristics, sampling methods and the criteria used to define chronic pain. Pain is a particular concern for cancer patients and has a significant impact on their QoL \[[@CR7]\]. Up to 70 % of patients with advanced cancer have been reported to experience chronic pain \[[@CR8], [@CR9]\].

Chronic pain can stem from a variety of underlying conditions, which may be musculoskeletal, neuropathic, ischaemic or cancer related \[[@CR2], [@CR10]\], and may be seen as a biopsychosocial phenomenon in which pain interacts with psychosocial factors \[[@CR11]\]. Chronic pain is also strongly associated with development of comorbidities, including depression and anxiety, impaired sleep and alterations in immune function \[[@CR5], [@CR12]--[@CR15]\].

Management strategies for chronic pain are multimodal, with the aim of reducing pain and maximizing QoL \[[@CR11], [@CR16]\]. Non-pharmacotherapeutic management may include physical and psychological interventions \[[@CR16]\]. The major pharmacological agents currently used to treat chronic pain include non-opioid analgesics (e.g. paracetamol and non-steroidal anti-inflammatory drugs, including cyclooxygenase-2 inhibitors) and opioids. In addition, atypical analgesics, including antidepressants and anticonvulsants, may be used. Pain intensity generally guides the process of analgesic choice and, in many cases, high-potency drugs are the first choice of treatment \[[@CR16], [@CR17]\]. For cancer pain, a stepwise approach to pharmacotherapy is generally advised on the World Health Organization (WHO) sequential three-step analgesic ladder from non-opioids to weak opioids, followed by strong opioids \[[@CR17]\]. Opioids, however, are the mainstay and sometimes the first-line option for pain relief in cancer pain, as they offer the most effective analgesic therapy \[[@CR7], [@CR18], [@CR19]\]. Recent clinical practice guidelines from the European Society for Medical Oncology and the European Association for Palliative Care (EAPC) state that low doses of morphine, oxycodone or a oxycodone--naloxone combination can be used as step II on the WHO ladder \[[@CR7], [@CR20]\]. Several medical societies have endorsed the use of opioids for non-cancer pain as a legitimate medical practice and have published guidelines for its safe use \[[@CR21]--[@CR23]\]. The value of opioid therapy, however, must be confirmed for each patient \[[@CR24]\]. Morphine is generally the opioid of choice for the treatment of moderate-to-severe chronic pain \[[@CR7], [@CR20]\]. Nonetheless, in a systematic review for an update of the EAPC guidelines, oxycodone was shown to be as effective as morphine and hydromorphone for cancer pain in terms of analgesia and is one of the most commonly used strong opioids in Europe \[[@CR7], [@CR25]\].

Maximizing QoL is particularly important in individuals with chronic pain, who may already suffer reduced QoL because of their pain \[[@CR26]\]. Several variables affect QoL, one of which is pharmacotherapy-related side effects. Despite the effectiveness of opioids, side effects compromise their therapeutic potential. Side effects may include nausea, central nervous system events such as confusion and hallucinations, pruritus and, particularly, opioid-induced bowel dysfunction (OIBD). OIBD includes a spectrum of symptoms, the primary one being opioid-induced constipation (OIC) \[[@CR27]--[@CR29]\]. With long-term use, many side effects associated with opioid therapy may subside because of tolerance; however, OIC often lingers and can significantly affect QoL \[[@CR2], [@CR28]\]. Optimal management of chronic pain with opioids requires a careful balance between efficacy and tolerability to ensure that QoL is maintained. One approach to overcome the gastrointestinal (GI) side effects of opioids is the use of opioid antagonists, such as naloxone, naloxegol, methylnaltrexone and alvimopan \[[@CR27], [@CR30]\]. Co-administration of oxycodone (a semi-synthetic opioid analgesic) with the opioid antagonist naloxone (OXN) has been demonstrated to counteract the GI side effects of the analgesic \[[@CR31]--[@CR33]\]. When administered orally, naloxone has low systemic bioavailability (\<2 %) and antagonizes peripheral opioid receptors in the GI tract with little impact on centrally acting opioid analgesia \[[@CR34]\]. In this review, we focus on the specific role of OXN in the management of chronic pain and OIC, and its impact on QoL and healthcare costs.

Opioid-Induced Bowel Dysfunction and Opioid-Induced Constipation {#Sec2}
================================================================

The GI tract plays a key role in the development of opioid-related adverse effects, as the main opioid receptors are widely distributed in the gut. Activation of GI opioid receptors by exogenous opioids disrupts GI motility and secretion, thereby inhibiting normal bowel function \[[@CR35]\]. The primary adverse effects of opioids frequently lead to secondary complications, including a constellation of signs and symptoms known as OIBD. OIBD comprises constipation, anorexia, nausea and vomiting, gastro-oesophageal reflux, delayed digestion, abdominal pain, flatulence, bloating, hard stools, straining during bowel movement and incomplete evacuation. In some cases, it may lead to more serious complications such as bowel faecal impaction with overflow diarrhoea and faecal incontinence, pseudo-obstruction (which may cause anorexia, nausea and vomiting), disturbance of drug absorption, urine retention and urine incontinence. These symptoms further the impact on patients' health \[[@CR35]--[@CR37]\] (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Primary and secondary symptoms and complications of opioid-induced bowel dysfunction. Adapted from Holzer \[[@CR27]\]. *GERD* gastroesophageal reflux disease

OIC can have a particularly significant impact on patients' lives \[[@CR37], [@CR38]\]. Estimates of the prevalence of constipation adverse effects in patients taking opioids varies because of variations in patient populations, differences in administration route, dose and type of the various opioids available \[[@CR29], [@CR39], [@CR40]\]. In patients with chronic non-cancer pain, prevalence rates of up to 90 % have been reported \[[@CR29], [@CR41]\]. In patients with cancer, a large series of US hospice studies reported prevalence rates of 40--63 % \[[@CR42]\]. In patients taking opioids, constipation has a serious impact on QoL and may be even more distressing for the patient than the pain itself \[[@CR26], [@CR43]--[@CR45]\]. In a large international survey of patients taking opioids for \>6 months, those suffering constipation were more likely to visit physicians, miss work and feel that their performance at work and their ability to undertake daily activities was impaired, compared with patients without constipation \[[@CR46]\]. Some patients may even discontinue opioid therapy because of symptoms of constipation \[[@CR47]\]. For these reasons, effective pharmacological therapy for OIC is considered to be an unmet need \[[@CR48]\].

Bowel dysfunction in patients with OIC, however, is not caused exclusively by the opioid medication. Factors such as pain, medications other than opioids, diet and underlying disease factors play an important role in the complex pathophysiology of constipation \[[@CR26]\].

Quality of Life in Patients with Chronic Pain {#Sec3}
=============================================

QoL is one of the most important patient-centred outcomes of medical care \[[@CR49], [@CR50]\] and is a multidimensional parameter for which coverage may be categorized within five dimensions: physical wellbeing, material wellbeing, social wellbeing, emotional wellbeing, and development and activity \[[@CR51]\]. In some individuals, such as older patients with long-term illness and those with no possible cure, QoL can be the only achievable outcome \[[@CR50]\]. In a comprehensive international study covering eight countries, it was demonstrated that suffering from a chronic condition substantially reduces QoL \[[@CR52]\].

Chronic pain is a condition that has a significant impact on the social and working lives of sufferers and may even lead to social isolation. A large pan-European study involving \>45,000 individuals suffering chronic pain reported that 21 % were diagnosed with depression due to their pain, 61 % were less able or unable to work outside the home, 19 % had lost their job and 13 % had changed jobs because of their pain \[[@CR2]\]. A total of 60 % of these individuals had visited their doctor for their pain 2--9 times in the previous 6 months \[[@CR2]\].

In addition to the reduced QoL due to pain, sufferers of moderate-to-severe pain treated with opioid medication often bear the additional burden of adverse effects of their pain medication, particularly OIC \[[@CR28], [@CR35]\]. Assessment of QoL in patients with OIC can assist therapeutic choices, and numerous assessment tools are available to assist in evaluation.

Tools to Measure Quality of Life in Patients with Chronic Pain and Constipation {#Sec5}
-------------------------------------------------------------------------------

Numerous tools are available to measure QoL in patients who have chronic pain and constipation. These tools can be general QoL measures that are designed to evaluate the effects of interventions or can be utility measures designed to evaluate judgements of health outcomes. A selection of QoL tools are listed in Table [1](#Tab1){ref-type="table"} \[[@CR53]\].Table 1Example instruments and tools available for measurement of quality of life in patients with pain and constipationGeneral health-related measures Medical Outcomes Study 36-Item Short-Form (SF-36) \[[@CR93]\]  Medical Outcomes Study 12-Item Short-Form (SF-12) \[[@CR94]\] Nottingham Health Profile \[[@CR95]\] World Health Organization Quality of Life (WHOQOL) pain subscale \[[@CR96]\]Utility measures^a^ EuroQoL \[[@CR97]\] Health Utilities Index (HUI) \[[@CR98]\]Cancer pain-specific tools Functional Living Index-Cancer (FLIC) \[[@CR99]\] Functional Assessment of Cancer Therapy-General (FACT-G) \[[@CR100]\] European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ) \[[@CR101]\]^b^Gastrointestinal-specific tools for constipation Gastrointestinal Symptom Rating Scale (GSRS) \[[@CR54]\] Elderly Bowel Symptom Questionnaire (EBSQ) \[[@CR55]\] Patient Assessment of Constipation Symptoms (PAC-SYM) \[[@CR56]\]^c^Specific quality of life for constipation Patient Assessment of Constipation Quality of Life (PAC-QoL) \[[@CR57]\]^d^Opioid-induced constipation-specific tools Bowel Function Index (BFI) \[[@CR58]\]^ea^SF-36 may be used as a utility measure^b^Developed for use in international clinical trials^c^A 12-item self-report instrument divided into abdominal, rectal and stool domains designed to assess symptom frequency and severity, and validated for use in patients with opioid-induced constipation^d^Includes four subscales: worries and concerns, physical discomfort, psychosocial discomfort and satisfaction^e^The BFI is owned by Mundipharma Laboratories GmbH, Switzerland (2002); the BFI is the subject of a European Patent Application (Publication No. EP 1,860,988) and corresponding patents and patent applications in other countries

Gastrointestinal-Specific Tools to Measure Quality of Life in Patients with Constipation {#Sec6}
----------------------------------------------------------------------------------------

Several tools are available to measure GI symptoms in patients with constipation (Table [1](#Tab1){ref-type="table"}). These include GI-specific tools for measuring constipation, including the Gastrointestinal Symptom Rating Scale \[[@CR54]\], the Elderly Bowel Symptom Questionnaire \[[@CR55]\] and the Patient Assessment of Constipation Symptoms (PAC-SYM) Questionnaire \[[@CR56]\]. The Patient Assessment of Constipation Quality of Life (PAC-QoL) was designed to include specific QoL outcomes for constipation; was developed to address the need for a standardized, patient-reported outcomes measure to evaluate constipation over time; and includes specific QoL-related measures \[[@CR57]\].

The Bowel Function Index: a Specific Validated Tool to Measure Bowel Function in Patients with Opioid-Induced Constipation {#Sec7}
--------------------------------------------------------------------------------------------------------------------------

The Bowel Function Index (BFI[1](#Fn1){ref-type="fn"}) is a validated, clinician-administered, patient-reported, three-item questionnaire (ease of defecation, feeling of incomplete evacuation and patient personal judgment of constipation) designed to evaluate OIC in cancer and non-cancer chronic pain patients \[[@CR58]--[@CR62]\]. Although not a direct measure of QoL, the BFI has been shown to be statistically correlated (*r* = 0.571; *p* \< 0.0001) with the Knowles--Eccersley--Scott symptom score and matches up with PAC-QoL and, to a lesser extent, with the Medical Outcomes Study 12-Item Short-Form (SF-12) generic QoL questionnaire \[[@CR63]--[@CR65]\].

Generic Quality-of-Life Measures {#Sec8}
--------------------------------

Generic QoL measures are becoming increasingly popular with health policy makers. One advantage of generic measures is that they are non-disease specific, so they allow the policy maker to compare the impact of therapies relative to therapies in another disease area. These measures are commonly applied in resource allocation decisions as policy makers are allocating budgets across multiple and diverse disease areas. The Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) is one of the most widely used generic QoL measures and has been used in articles describing more than 200 diseases and conditions \[[@CR66], [@CR67]\]. One special type of QoL measure is the utility value, which is implied in health economic models based on a cost-utility analysis \[[@CR68], [@CR69]\]. Utility score health is usually measured between 0 and 1, where perfect health is given a score of 1 (although, in extreme cases, the score can go below 0, which is classified as 'worse than death'). There have been a number of utility studies showing the reduction in QoL due to constipation. One study in patients with a severe non-curable disease and relatively short life expectancy treated with opioids found that QoL, as measured by the EuroQoL five-dimension questionnaire (EQ-5D), for those without advanced illness who were not constipated, was much higher (score 0.65) than the score for those who were constipated (score 0.31) \[[@CR44]\]. In another study in patients with chronic functional constipation, a cost-utility model used to define health status in terms of the number of quality-adjusted life years (QALYs) demonstrated a 1 % improvement in health gain for one laxative over another \[[@CR70]\].

Economic Burden of Constipation {#Sec9}
===============================

The economic burden of constipation is vast in terms of both direct and indirect costs \[[@CR26], [@CR71]\]. Constipation-associated direct costs include physician visits, hospitalization, procedures and medications. Indirect costs include self-medication, lost earnings, restricted activity and costs of caregivers \[[@CR26]\]. In studies conducted in the USA in patients receiving opioid treatment, direct costs have been demonstrated to be significantly higher in patients reporting GI events and constipation than in those not reporting such events \[[@CR72], [@CR73]\]. In an analysis of the costs of medical and pharmacy claims in patients receiving a new prescription for oral, short-acting opioid treatment, adjusted mean healthcare costs per patient during the 90 days after the opioid therapy were more than ten times higher for patients experiencing GI events than for those without GI events (US\$40,133 versus US\$3,981) \[[@CR72]\]. A study conducted in Sweden in patients treated with strong opioids demonstrated that total (direct and indirect) costs are particularly high in patients with severe constipation, reaching €1,525 per patient per month, compared with €1,034 for patients with no constipation (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR74]\]. In cancer patients on opioid therapy, costs associated with constipation were found to be especially significant, with increases in total costs of 109 % for patients who had constipation, compared with those who did not \[[@CR71]\]. Patients with constipation had significantly higher rates of concurrent use of ≥2 opioids, opioid discontinuation, opioid switching, nausea with vomiting, and respiratory depression than those without constipation. Patients with constipation also received more in-patient, hospice, home health, laboratory, other outpatient, emergency, office visit and nursing home care \[[@CR71]\]. Resource utilization associated with the diagnosis and management of constipation is a significant cost driver, and constipation prevention programmes can lead to substantial cost savings \[[@CR26]\].Fig. 2Mean cost per patient per month for opioid-treated patients with and without constipation \[[@CR74]\]

Strategies for the Management of Opioid-Induced Constipation {#Sec10}
============================================================

Strategies for managing OIC include rotation or reduction in the dose of the opioid and management of OIC symptoms \[[@CR75]\]. There are currently two main strategies for the management of OIC symptoms: the use of laxatives and treatment with opioid antagonists.

Laxatives {#Sec11}
---------

Laxatives are the most common therapeutic strategy for OIC \[[@CR76]\]. Conventional laxatives either act by affecting osmotic condition, stimulate bowel action or have emollient properties. Inhibition of small-intestinal motility is a prominent feature of opioids and is probably one of the reasons why laxatives (which act predominantly on the colon) do not have a satisfactory effect on the majority of patients with OIC \[[@CR40]\]. In addition, laxatives have the potential for over-use and dependency, and are associated with adverse effects such as dehydration, bloating and dermatitis \[[@CR29], [@CR37]\]. Despite the wide availability of different laxative types, OIC persists in many patients. In a multinational survey (PROBE 1), 45 % of patients receiving opioids and laxatives reported fewer than three bowel movements per week, 81 % of patients reported constipation and 58 % reported straining to pass a bowel movement \[[@CR40]\]. In another study, 54 % of patients did not achieve a desired result with laxatives even half of the time. Despite the fact that OIC is usually treated with laxatives, there is insufficient clinical evidence that laxatives are efficacious in this indication \[[@CR77]\]. In addition, it appears that laxatives are often not prescribed, even when they are indicated. In an audit of clinical practice in Scotland, 98 % of opioid prescriptions for patients needing an opioid were for the opioid alone \[[@CR78]\].

Opioid Antagonists {#Sec12}
------------------

Opioid antagonists aim to counteract the constipation effects of opioids by antagonizing the peripheral opioid receptors in the GI tract, while avoiding an impact on centrally acting opioid analgesia \[[@CR79], [@CR80]\]. The main challenge with opioid antagonists is to inhibit peripheral actions without affecting their central action, which may lead to opiate withdrawal symptoms or reversal of the analgesic effect \[[@CR79]\]. Several single-entity opioid antagonists, including peripherally acting mu-opioid receptor antagonists (PAMORAs), are available and in development. These include methylnaltrexone, naloxegol and alvimopan \[[@CR81]\]. Methylnaltrexone, which is administered as an emergency-relief subcutaneous injection when traditional oral laxatives fail, provides a bowel movement in approximately 50--60 % of patients but is approved only for palliative care in patients with advanced illness \[[@CR75], [@CR82]\]. Alvimopan, which is approved by the US Food and Drug Administration (FDA) and is indicated to accelerate the time to upper and lower GI recovery following surgeries that include partial bowel resection with primary anastomosis, has also been shown to increase spontaneous bowel movements, but cardiovascular safety concerns have hindered development of this agent \[[@CR81]\]. Naloxegol has been recently approved by the FDA as an add-on to existing pain therapy and has shown efficacy for increasing bowel movements \[[@CR81]\]. Oral formulations such as naloxegol and alvimopan provide obvious advantages over methylnaltrexone in terms of patient acceptance and QoL. However, these single-entity agents need to be combined with analgesic agents and therefore carry an intrinsic risk of lower patient compliance. Unfortunately, as yet, there are no directly comparative published data for these PAMORAs, but individual efficacy and safety analyses have been reviewed in several publications elsewhere \[[@CR30], [@CR81], [@CR83], [@CR84]\].

Naloxone is a competitive antagonist of peripheral opioid receptors with low systemic bioavailability and therefore has little impact on centrally acting opioid analgesia \[[@CR34]\]. Naloxone, as part of a prolonged-release (PR) combination, reverses opioid-induced peripheral GI effects \[[@CR85]\]. In patients with moderate-to-severe chronic pain, phase II and phase III randomized trials have demonstrated that combination PR oxycodone/naloxone (OXN PR) has equal analgesic efficacy and safety, but with improved bowel function, compared with oxycodone alone \[[@CR31]--[@CR33], [@CR86], [@CR87]\]. The beneficial effects of OXN PR, compared with oxycodone, have also been demonstrated over the long term (\<52 weeks) \[[@CR88]\].

Quality-of-Life Benefits of Oxycodone/Naloxone {#Sec13}
----------------------------------------------

In the trials evaluating OXN PR, bowel function and QoL were investigated using the BFI and other tools (Table [2](#Tab2){ref-type="table"}). In the three phase III trials, conducted mainly in patients with moderate-to-severe non-malignant pain, significant improvements in the BFI were seen in patients taking OXN PR versus those taking oxycodone PR (Oxy PR) \[[@CR31]--[@CR33]\] (Table [2](#Tab2){ref-type="table"}). These improvements were generally seen after just 1 week of treatment and continued throughout the trials \[[@CR31]--[@CR33]\]. Significant and clinically relevant improvements in symptoms, using PAC-SYM and the Patient Assessment of Opioid-Induced Constipation, were also demonstrated \[[@CR31]--[@CR33]\]. The improvements in bowel function were confirmed in a pooled analysis of the phase III trials, in which significant improvements were demonstrated in the BFI for patients receiving OXN PR, compared with those receiving Oxy PR \[[@CR87]\]. Statistically significant and clinically relevant improvements in the BFI were observed at week 1 and at every subsequent time point during the study (−15.1; 95 % CI −17.3 to −13.0; *p* \< 0.0001 versus baseline) (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR87]\]. Similar significant improvements in QoL in terms of the BFI were demonstrated in a randomized phase II study in patients with severe chronic pain \[[@CR86]\]. A 52-week extension study, in which patients were maintained on OXN PR or switched from Oxy PR to OXN PR, demonstrated that these improvements in the BFI are maintained over the long term \[[@CR88]\]. In an evaluation of OXN PR, using the generic QoL tool SF-36, significant improvements were seen in social functioning (*p* = 0.012), vitality (*p* = 0.010) and the general health subscale (*p* = 0.039) at week 12 \[[@CR89]\].Table 2Overview of quality-of-life-based outcomes using the Bowel Function Index (BFI) in prolonged-release (PR) oxycodone/naloxone (OXN) clinical trialsTrial designPopulationMeasureResultsReferences1.12-week, phase III RCT\
Combined OXN PR vs Oxy PR\
Primary objective: constipation as measured by BFIModerate-to-severe non-malignant painBFI\
PAC-SYMSignificant improvement for OXN PR vs Oxy PR in BFI at 4 weeks (treatment difference: −14.9; *p* \< 0.0001)\
Clinically relevant improvement in PAC-SYM\
Most common AEs were GI (24 % for OXN PR vs 16 % for Oxy PR)Lowenstein et al. \[[@CR31]\]2.12-week, phase III RCT\
Combined OXN PR vs Oxy PR\
Primary objective: constipation as measured by BFIModerate-to-severe non-cancer painBFI\
PACOISignificant improvement for OXN PR vs Oxy PR in BFI at 4 weeks (treatment difference: −15.2; *p* \< 0.0001)\
Significant improvement in PACOI at 4 weeks (*p* \< 0.0001)\
Most common AEs were GI (19 % for OXN PR vs 30 % for Oxy PR)Simpson et al. \[[@CR33]\]3.12-week, phase III RCT\
Combined OXN PR vs Oxy PR vs PBO\
Primary objective: analgesic efficacy\
Constipation, as measured by BFI, was an exploratory analysisModerate-to-severe non-malignant lower back painBFI\
BPI-SF (modified)^a^Clinically relevant improvement in BFI\
Mean BFI reduction vs baseline at 12 weeks: −23 for OXN PR vs −11 for Oxy PR^b^\
Significant improvement in BPI-SF for OXN PR (*p* = 0.0057) and Oxy PR (*p* = 0.0030) vs PBO\
Most common AEs were GI (23 % for OXN PR vs 27 % for Oxy PR)Vondrackova et al. \[[@CR32]\]4.12-week, phase II RCT\
Oxy PR + naloxone PR vs Oxy PR\
Primary objectives: constipation, as measured by BFI, and analgesic efficacy, including optimal dose identification (oxycodone to naloxone ratio)Severe chronic non-cancer pain and cancer pain (2.5 % of patients)BFISignificant improvement in BFI at 4 weeks (treatment difference: −16.2; *p* \< 0.05 for 2:1 ratio group)\
Similar overall AEs between groups (62--70 %)Meissner et al. \[[@CR86]\]5.Pooled analysis of trial 1 (Lowenstein et al. \[[@CR31]\]) and trial 2 (Simpson et al. \[[@CR33]\])\
Primary objective: analgesic efficacy\
Constipation, as measured by BFI, was an secondary end pointModerate-to-severe non-malignant painBFISignificant improvement in BFI at 12 weeks (−15.1; *p* \< 0.0001)\
Most common AEs were GI (21 %)Lowenstein et al. \[[@CR87]\]6.Long-term (≤52 weeks) open-label extension of trial 3 (Vondrackova et al. \[[@CR32]\]) and trial 2 (Simpson et al. \[[@CR33]\])\
OXN PR\
No primary end point was set. Analgesic efficacy and constipation, as measured by BFI, were assessed as two separate analyses^c^Moderate-to-severe non-cancer painBFIBFI reduction vs baseline at 12 months (−15)\
Most common AEs were infections and infestations (40 %)Sander-Kiesling et al. \[[@CR88]\]*AE* adverse event, *BFI* Bowel Function Index, *BPI* Brief Pain Inventory, *GI* gastrointestinal, *Oxy* oxycodone, *PACOI* Patient Assessment of Opioid-Induced Constipation (sum score of the rectal and stools subscale score of PAC-SYM), *PAC-SYM* Patient Assessment of Constipation Symptoms, *PBO* placebo, *RCT* randomized controlled trial, *SF* Short Form^a^BPI interference of pain with sleep item^b^Subgroup of patients with BFI ≥50 at baseline; no statistical analysis was conducted on this patient population^c^Results for BFI analysis are reported hereFig. 3Mean Bowel Function Index score over time in patients treated with prolonged-release (PR) oxycodone/naloxone and oxycodone PR (pooled analysis of two randomized phase III trials) \[[@CR87]\]

In real-world clinical practice, a large non-interventional study reported improvements in QoL for patients taking OXN PR \[[@CR90]\]. In this German study involving 7,836 individuals with severe chronic pain of various aetiologies treated with OXN PR, significant reductions in the BFI were seen both in opioid-naïve and opioid pre-treated patients \[[@CR90]\]. QoL, as measured by the Short-Form Brief Pain Inventory (BPI-SF), demonstrated an improvement of 43 % in mean overall QoL (in 2,023 individuals) after just 4 weeks of treatment \[[@CR90]\].

Health Economic Benefits of Oxycodone/Naloxone {#Sec14}
----------------------------------------------

A UK comparison of the cost effectiveness of OXN PR versus Oxy PR, using a cost-utility model combining the costs of pain therapy, laxatives and other resources to manage constipated patients with moderate-to-severe non-malignant pain, demonstrated a QoL gain with OXN PR versus Oxy PR \[[@CR89]\]. The incremental gain in QALYs was based on the SF-36 results mapped to EQ-5D and implied that patients treated with OXN PR in real-world clinical practice will experience a QoL gain. Treatment costs were slightly higher for OXN PR, but this was offset by increased QALY gains. The ratio of incremental cost to incremental QALY gain was substantially below commonly applied decision thresholds in the UK, suggesting that OXN PR is cost effective and should be adopted in the health system \[[@CR89]\]. In some scenarios, total cost savings to the health system have been demonstrated. In a German study in which patients received OXN PR or other strong (WHO step III) opioids at 6 months, direct treatment costs were lower in the OXN PR cohort, and there was a QALY gain, compared with the cohort taking other strong opioids \[[@CR91]\]. Similar results were seen in a Spanish study in patients with chronic severe pain and OIC, in which an incremental cost-effectiveness ratio far below the efficiency threshold commonly cited in Spain was demonstrated \[[@CR92]\].

Conclusions {#Sec15}
===========

Management of chronic pain is challenging, and unmet needs remain. Traditional opioids are often the treatment of choice in moderate and severe pain, but their use is often compromised by side effects; in particular, OIBD can substantially reduce QoL. Most treatments for OIBD are not very effective and are not mechanism based. OXN is one of the first therapies to act directly on the mechanism of OIBD and has been shown to be an effective treatment for this (to date, unmet) need.

The BFI is a specific validated measurement tool that can assist in the evaluation of bowel function in patients with OIBD, and specifically with OIC. Treatment of patients with moderate-to-severe pain with OXN PR has been demonstrated to significantly improve QoL. Use of OXN PR should allow more patients to benefit from the analgesic efficacy of opioid therapy and should minimize the side effects of constipation, with a corresponding improvement in QoL. Health economic analysis has shown OXN PR to be below commonly applied thresholds, with some cost offsets because of fewer resources being required to treat the constipation.

The BFI is owned by Mundipharma Laboratories GmbH, Switzerland (2002); the BFI is the subject of a European Patent Application (Publication No. EP 1,860,988) and corresponding patents and patent applications in other countries.
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